UHKT-CAR19

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug NameUHKT-CAR19

Drug Alias Nameanti-CD19 CAR T-cell therapy (Institute of Hematology and Blood Transfusion)

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsT lymphocytes stimulantsImmunostimulants

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsLymphoma, Non-HodgkinPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCzechia

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesInstitute of Hematology and Blood Transfusion, Czech Republic

China Registration ClassN/A

Develop Information

Active CompaniesInstitute of Hematology and Blood Transfusion, Czech Republic

Inactive CompaniesN/A

Active IndicationsLymphoma, Non-HodgkinPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A